Codon-specific KRAS mutations predict survival benefit of trifluridine/tipiracil in metastatic colorectal cancer
Codon-specific KRAS mutations predict survival benefit of trifluridine/tipiracil in metastatic colorectal cancer is a paper indexed in ScholarIQ from OpenAlex.
How many citations does Codon-specific KRAS mutations predict survival benefit of trifluridine/tipiracil in metastatic colorectal cancer have?
Codon-specific KRAS mutations predict survival benefit of trifluridine/tipiracil in metastatic colorectal cancer has 84 citations in the OpenAlex counts ScholarIQ stores.
When was Codon-specific KRAS mutations predict survival benefit of trifluridine/tipiracil in metastatic colorectal cancer published?
Codon-specific KRAS mutations predict survival benefit of trifluridine/tipiracil in metastatic colorectal cancer has 2023 year in the ScholarIQ index.
What is the open-access status of Codon-specific KRAS mutations predict survival benefit of trifluridine/tipiracil in metastatic colorectal cancer?
Codon-specific KRAS mutations predict survival benefit of trifluridine/tipiracil in metastatic colorectal cancer has hybrid oa status in the ScholarIQ index.
What is the DOI of Codon-specific KRAS mutations predict survival benefit of trifluridine/tipiracil in metastatic colorectal cancer?
The DOI for Codon-specific KRAS mutations predict survival benefit of trifluridine/tipiracil in metastatic colorectal cancer is on the source record.
What is the PMID of Codon-specific KRAS mutations predict survival benefit of trifluridine/tipiracil in metastatic colorectal cancer?
The PMID for Codon-specific KRAS mutations predict survival benefit of trifluridine/tipiracil in metastatic colorectal cancer is on the source record.
What is the OpenAlex record for Codon-specific KRAS mutations predict survival benefit of trifluridine/tipiracil in metastatic colorectal cancer?
The OpenAlex for Codon-specific KRAS mutations predict survival benefit of trifluridine/tipiracil in metastatic colorectal cancer is on the source record.